Evelo Biosciences to Report First Quarter 2021 Financial Results on Thursday, April 29, 2021
April 22 2021 - 7:00AM
Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology
company developing a new modality of orally delivered medicines,
today announced that it will host a conference call and live
webcast at 8:30 a.m. ET on Thursday, April 29, 2021 to report its
first quarter 2021 financial results and discuss business
highlights.
To access the live conference call, please dial 866-795-3242
(domestic) or 409-937-8909 (international) and refer to conference
ID 5856668. A live webcast of the event will also be available
under “News and Events” in the Investors section of Evelo's website
at http://ir.evelobio.com. The archived webcast will be
available on Evelo's website approximately two hours after the
completion of the event and will be available for 30 days following
the call.
About Evelo BiosciencesEvelo
Biosciences is a clinical stage biotechnology company developing
orally delivered medicines that act on SINTAX™, the small
intestinal axis, and to have systemic therapeutic effects. SINTAX
plays a central role in governing the immune, metabolic, and
neurological systems. The Company’s first product candidates are
pharmaceutical preparations of single strains of microbes selected
for defined pharmacological properties.
Evelo currently has four product candidates in
development: EDP1815, EDP1867, and EDP2939 for the treatment of
inflammatory diseases and EDP1908 for the treatment of cancer.
Evelo is advancing additional product candidates in other disease
areas.
For more information, please visit
www.evelobio.com and engage with Evelo on LinkedIn and video.
ContactJessica Cotrone,
978-760-5622jcotrone@evelobio.com
Evelo Biosciences (NASDAQ:EVLO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evelo Biosciences (NASDAQ:EVLO)
Historical Stock Chart
From Apr 2023 to Apr 2024